Business Context and Reporting Period
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections. This Form 10-Q covers the quarterly period ended June 30, 2025. The Company is currently a non-accelerated filer and a smaller reporting company. Its primary strategic focus has shifted to the development of tebipenem HBr following the suspension of the SPR720 oral program and the discontinuation of the SPR206 program.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $14.2 million | $10.2 million | $20.1 million | $19.5 million |
| Net Loss | $(1.7) million | $(17.9) million | $(15.6) million | $(30.5) million |
| Net Loss Per Share | $(0.03) | $(0.33) | $(0.28) | $(0.57) |
| Operating Expenses | $16.6 million | $29.3 million | $37.2 million | $52.5 million |
| Cash and Cash Equivalents (End of Period) | $31.2 million | $63.5 million | $31.2 million | $63.5 million |
| Accumulated Deficit | $(475.2) million | $(421.6) million | $(475.2) million | $(421.6) million |
Liquidity and Debt: As of June 30, 2025, the Company held $31.2 million in cash and cash equivalents. There is no long-term debt reported. The Company expects its cash runway, combined with non-contingent milestone payments from GSK, to fund operations into 2028.
Material Changes vs. Prior Period
- Revenue Composition: Collaboration revenue from the related party (GSK) increased significantly to $11.8 million in Q2 2025 from $5.9 million in Q2 2024. This increase was driven by a cumulative catch-up revenue recognition adjustment following the early stop of the PIVOT-PO Phase 3 trial for efficacy. Grant revenue decreased to $2.4 million from $4.2 million due to reduced activity under the BARDA contract.
- Expense Reduction: Total operating expenses decreased by approximately $12.6 million in Q2 2025 compared to Q2 2024. Research and Development (R&D) expenses dropped from $23.7 million to $10.7 million, primarily due to the cessation of clinical activities for the PIVOT-PO trial and the suspension of the SPR720 program.
- Restructuring: The Company incurred $0.1 million in restructuring charges in Q2 2025, related to a workforce reduction initiated in October 2024. No restructuring charges were recorded in the prior year period.
- Cash Position: Cash and cash equivalents decreased by $21.7 million during the six months ended June 30, 2025, compared to a decrease of $12.8 million in the same period in 2024. The decrease was primarily due to net cash used in operating activities.
Guidance, Outlook, and Risks
- Clinical Milestone: In May 2025, the Company announced that the pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint and was stopped early for efficacy. GSK plans to submit a New Drug Application (NDA) in the second half of 2025.
- Program Status: Development of the SPR720 oral program was suspended in October 2024 after failing to meet its primary endpoint. Development of SPR206 was discontinued in March 2025.
- Outlook: Management believes current cash resources and expected GSK milestone payments (including a $23.8 million payment received in Q3 2025) are sufficient to fund operations into 2028. The Company expects to continue incurring operating losses until product commercialization.
- Legal and Regulatory Risks:
- SEC Wells Notice: The Company received a Wells Notice from the SEC in January 2025 regarding potential civil enforcement actions related to public disclosures made in 2022. The Company maintains its disclosures were appropriate but faces uncertainty regarding potential penalties or injunctions.
- Nasdaq Compliance: The Company previously received a deficiency letter regarding its bid price but regained compliance with Nasdaq listing requirements in June 2025.
- Government Contracts: The NIAID contract for SPR206 was terminated for convenience in April 2025.
Investor Verification Checklist
- SEC Investigation Status: Verify the current status of the SEC Wells Notice and any potential impact on the Company's ability to raise capital or maintain its listing.
- GSK Milestone Payments: Confirm the timing and certainty of the remaining $23.8 million GSK milestone payment expected in Q3 2025 and the $25.0 million NDA submission milestone.
- Cash Runway: Assess the Company's burn rate and the sufficiency of the $31.2 million cash balance to fund operations through 2028 without additional financing.
- Regulatory Path: Monitor the timeline for GSK's NDA submission for tebipenem HBr and the FDA's review process.
- Program Discontinuation: Review the strategic implications of suspending SPR720 and discontinuing SPR206 on the Company's long-term pipeline diversity.